title: [Cost of screening for hepatocarcinoma in patients with cirrhosis: a prospective study].
abstract: BACKGROUND
  Current clinical guidelines recommend biannual screening for hepatocarcinoma in cirrhotic patients; however, the cost of this preventive activity is unknown.
  
  
  OBJECTIVE
  To determine the cost of ultrasound screening for hepatocarcinoma in patients with cirrhosis.
  
  
  METHODS
  Data on patients diagnosed with liver cirrhosis in a population of 245,042 inhabitants were prospectively gathered. The screening tests performed and cases of hepatocarcinoma diagnosed during the annual follow-up were included in the analysis. The cost of these tests was calculated based on the tariffs paid by insurance companies for health coverage of civil servants.
  
  
  RESULTS
  In 2009, there were 374 patients with cirrhosis; of these, 99 were aged > 80 years, with a performance status of >2 or associated comorbidities. During the annual follow-up, the remaining patients underwent a total of 602 visits (abdominal ultrasound, blood test), four contrast-enhanced computed tomography scans, nine magnetic resonance scans, two scintigraphies, four aspiration biopsies, four radiographs and six contrast ultrasound scans. In our environment, the total estimated cost of these procedures was 37,946 €, indicating that the cost of a screening program for hepatocellular carcinoma according to the above-mentioned selection criteria is 0.155 € per inhabitant/year. If only cirrhotic patients suitable for screening are included, the annual cost of screening is 138 € per patient.
  
  
  CONCLUSIONS
  The cost of an ultrasound screening program for hepatocarcinoma is 0.155 € per inhabitant/year. These data should be taken into account when considering population-based screening programs.
authors.affiliation: Servicio de Aparato Digestivo, Hospital Sant Joan de Déu, Althaia Xarxa Hospitalaria de Manresa, Manresa, Barcelona, España. sortjane@althaia.cat
authors.forename: Pau
authors.initials: P
authors.lastname: Sort
authors.forename: Marco Antonio
authors.initials: MA
authors.lastname: Alvarez
authors.forename: Anna
authors.initials: A
authors.lastname: Bargalló
authors.forename: Alvaro
authors.initials: A
authors.lastname: Isava
authors.forename: María
authors.initials: M
authors.lastname: Muñoz
authors.forename: Francesc
authors.initials: F
authors.lastname: Porta
authors.forename: Eva
authors.initials: E
authors.lastname: Rodríguez
authors.forename: Francesc
authors.initials: F
authors.lastname: Vida
mesh_terms: D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle / Q000191:economics; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D015897:Comorbidity; D003365:Costs and Cost Analysis; D055088:Early Detection of Cancer; D005260:Female; D006801:Humans; D007349:Insurance, Health, Reimbursement / Q000706:statistics & numerical data; D008103:Liver Cirrhosis / Q000150:complications / Q000000981:diagnostic imaging* / Q000191:economics; D008111:Liver Function Tests / Q000191:economics; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D008279:Magnetic Resonance Imaging / Q000191:economics; D008297:Male; D008403:Mass Screening / Q000191:economics*; D015995:Prevalence; D011446:Prospective Studies; D011877:Radionuclide Imaging / Q000191:economics; D014057:Tomography, X-Ray Computed / Q000191:economics; D014463:Ultrasonography